# Angiodynamics Inc: Form 10-Q for the period ended Feb 28, 2009

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2009-04-09
- Accepted by EDGAR: Apr 9, 2009, 19:08 ET
- Period: 2009-02-28
- Accession: 0001193125-09-076451
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000119312509076451/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000119312509076451/

## Management's discussion and analysis

As filed, 36,976 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company’s expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the ability of the Company to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in the Company’s reports filed with the SEC, including the Company’s Form 10-K for the fiscal year ended May 31, 2008.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Overview

AngioDynamics is a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD, and local oncology therapy options for treating cancer, including radiofrequency ablation (“RF” or “RFA”) systems, irreversible electroporation (“IRE”) surgical resection systems and embolization products for treating benign and malignant tumors. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, interventional and surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. For the past five fiscal years, over 95% of our net sales were from single-use, disposable products.

Historically, we reported our results of operations as a single segment. Beginning with fiscal 2009, we have organized our business into three reportable segments: Peripheral Vascular, Access and Oncology/Surgery. The Peripheral Vascular segment is comprised of the venous, angiographic, PTA, drainage and thrombolytic product lines. The Access segment is comprised of the dialysis, ports and PICC product lines. The Oncology/Surgery segment is comprised of the RFA, embolization, Habib and NanoKnife product lines. Prior periods have been recast for net sales and gross profit for this new reporting structure.

We sell our broad line of quality devices in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. As of February 28, 2009, our sales organization numbered 132 in the U.S. and 15 outside the U.S. For the three and nine months ended February 28, 2009, approximately 11% of our net sales were from non US markets, compared with approximately 9% in the same periods of the prior year.

Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing and strategic alliances. For each of the past three fiscal years, we invested at least 7% of our net sales in research and development (“R&D”). R&D expenditures were approximately 9% of net sales for the three and nine months ended February 28, 2009. We expect that our R&D expenditures will be approximately 9% of net sales for fiscal 2009 primarily due to investment in IRE technology. We expect R&D expenditures thereafter to continue to be in the range of 9% of net sales due to continued investment in IRE technology and other technology. However, downturns in our business could cause us to reduce our R&D spending.

We are also seeking to grow through selective acquisitions of complementary businesses and technologies. In January 2007, we completed the acquisition of RITA Medical Systems, Inc. This acquisition created a diversified medical technology company with a broad line of access, diagnostic and therapeutic products that enable interventional physicians and surgeons to treat peripheral vascular disease and cancerous tumors. Interventional oncology is a large and growing area for our existing customer base and RITA’s leadership position, premium products and excellent reputation fit our strategy. RITA had a very strong position in vascular access ports, which are an ideal sales fit with our Morpheus ® CT PICC and the vascular access port technology we purchased from Medron in May 2006. In addition, in May 2008 we acquired irreversible electroporation (IRE) technology which will be complementary to RITA’s diverse offering of local oncology therapies, including its market-leading RFA systems, Habib Sealer TM resection devices and LC Beads TM for tumor embolization. We are in the process of commercializing the IRE technology and recently introduced the NanoKnife generator. In June 2008, we completed the acquisition of certain U.S. and U.K. assets of Diomed, Inc. With this acquisition, we substantially strengthened our position in the market for the treatment of varicose veins. The combination of Diomed endovenous laser products with our existing venous product line provides us with a comprehensive venous product offering. In January 2009, we completed the acquisition of certain assets of FlowMedica, Inc. providing us with the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy.

Except to the extent we can further use our cash and short term investments or our equity securities as acquisition capital, we will require additional equity or debt financing to fund any future significant acquisitions.

In recent years, we expanded our manufacturing and warehousing facilities in Queensbury, New York, to provide us with significantly greater manufacturing and warehousing capacity and to accommodate additional research, development and administrative requirements. We are not currently operating our manufacturing facilities at full capacity. However, we anticipate requiring additional office space for additional engineering, marketing and administrative personnel in the near future.

Our ability to further increase our profitability will depend in part on improving gross profit margins. Factors such as changes in our product mix, new technologies and unforeseen price pressures may cause our margins to grow at a slower rate than we have anticipated, or to decline.

### Recent Developments

#### Acquisition of FlowMedica, Inc.

On January 12, 2009 we completed the acquisition of certain assets of FlowMedica, Inc. for approximately $1.75 million in cash and a contingent payment based on fiscal 2011 sales of FlowMedica products. With this acquisition, we purchased the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy. Intangible assets acquired totaled approximately $1.3 million which have been identified as product technologies (13-year weighted average useful life.) Inventory acquired totaled approximately $400,000. The acquisition is being accounted for as a purchase and accordingly, we have included the results of operations in the financial statements effective January 12, 2009. The pro-forma effects of the acquisition were not material to our income statement and balance sheet. Ten employees of FlowMedica, Inc. became employees upon completion of the acquisition.

#### Acquisition of certain assets of Diomed

On June 17, 2008, we completed the acquisition of certain U.S. assets of Diomed, Inc. and UK assets of Diomed UK Limited., in separate transactions, for an aggregate purchase price of approximately $11.1 million in cash including capitalized acquisition costs. With this acquisition, we substantially strengthened our position in the market for the treatment of varicose veins. The combination of Diomed endovenous laser products with our existing venous product line provides us with a comprehensive venous product offering. The total of the net tangible assets acquired was $5.5 million. Goodwill recorded as a result of these acquisitions was approximately $1.9 million. Intangibles assets acquired, other than goodwill, totaled approximately $3.7 million of which $3.6 million has been identified as customer relationships (8 -year estimated weighted average useful life) and $100,000 has been identified as product technologies (10 -year estimated weighted average useful life).

The acquisition is being accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective June 17, 2008. The pro-forma effects of the Diomed acquisition on our income statement and balance sheet were not material. Thirty five employees of Diomed became employees of ours upon completion of the acquisition.

#### Acquisition of Oncobionic, Inc.

On May 9, 2008, we completed the acquisition of all the issued and outstanding shares of capital stock of Oncobionic, Inc. pursuant to the terms of the Stock Purchase Agreement entered into on October 12, 2006. The closing of the acquisition comes as a result of the successful use of irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008.

Under the October 2006 Stock Purchase Agreement, we agreed to pay a total purchase price of $25.4 million, including $400,000 of assumed liabilities. We made payments of $5.0 million upon the execution of the stock purchase agreement in October 2006, $10.0 million on May 9, 2008 upon the closing of the acquisition, and $5.0 million in November 2008. The remaining $5.0 million is payable in November 2009.

The Stock Purchase Agreement also provides for future royalty payments due on net sales of any catheter-based products sold by us that incorporate irreversible electroporation technology (“IRE”). We hold a license to such technology under a license agreement with the Regents of the University of California (the “UC License”).

We have accounted for the acquisition of Oncobionic as a purchase under accounting principles generally accepted in the United States of America. Under the purchase method of accounting, the assets and liabilities of Oncobionic were recorded as of the acquisition date, at their respective fair values, and consolidated with those of AngioDynamics. Substantially all of the purchase price was recorded as product technology and is being amortized over a 15 year useful life. We have recorded goodwill and a deferred tax liability of $9.3 million. In future periods the deferred tax liability will be reduced to offset the tax impact of non-deductible amortization expense on the intangible assets acquired. The pro-forma impact on prior year results of operations for the nine month period would be approximately $1,260,000 of additional amortization expense or $780,000, net of tax.

### Results of Operations

### Three Months ended February 28, 2009 and February 29, 2008

Financial Summary. For the third quarter of fiscal 2009, we reported net income of $1.9 million, or $0.08 per diluted common share, on net sales of $49.4 million, compared with net income of $4.9 million, or $0.20 per diluted common share, on net sales of $40.7 million in the third quarter of the prior year. Gross profit was 61.1% in the third quarter of fiscal 2009 compared with 62.2% in the third quarter of the prior year.

The following table sets forth certain operating data as a percentage of net sales:

|  | Three Months Ended February 28, 2009 | February 29, 2008 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 61.1% | 62.2% |
| Research and development expenses | 9.5% | 9.7% |
| Sales and marketing expenses | 27.6% | 28.8% |
| General and administrative expenses | 14.0% | 8.4% |
| Amortization of intangibles | 4.7% | 4.4% |
| Gain on litigation settlement | 0.0% | -7.7% |
| Operating income | 5.3% | 18.7% |
| Other income(expenses) | 0.2% | 0.6% |
| Net income | 3.9% | 12.0% |

Net sales. Net sales for the fiscal third quarter of 2009 increased by 21%, or $8.7 million, to $49.4 million, from $40.7 million in the fiscal third quarter of 2008. $5.2 million of the $8.7 million was attributable to increased sales of laser ablation products, including those acquired from Diomed. The balance of the growth in net sales was primarily attributable to increased unit sales of LC Bead and the SmartPort CT.

From a business unit perspective, Peripheral Vascular sales increased 35% to $20.7 million from $15.4 million. $5.2 million of the increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. Laser ablation sales increased from $3.1 million in the fiscal third quarter of 2008 to $8.3 million in the fiscal third quarter of 2009, reflecting the acquisition of Diomed and the integration of the VenaCure EVLT product line. Access sales were $17.2 million, an increase of 8%, primarily attributable to increased unit sales of SmartPort CT. Oncology/Surgery sales were $11.5 million, an increase of 22% over the prior year primarily as a result of strong sales of our chemoembolization product, LC Bead.

From a geographical perspective, US sales increased $7.1 million or 19% in the third quarter of 2009 to $44.1 million from $37.0 million a year ago. Approximately $3.3 million of this increase is attributable to the sales of products acquired from Diomed. The balance of this increase is primarily attributable to increased unit sales of LC Bead and the SmartPort CT. International sales increased $1.7 million or 45% in the third quarter of 2009 to $5.4 million from $3.7 million a year ago. Approximately $1.9 million of this increase is attributable to the sales of products acquired from Diomed, offset by decreased sales of our RF Ablation devices. IRE products (Nanoknife) contributed $110,000 in the third quarter of 2009 in International Oncology/Surgery business segment sales.

Gross profit. Our gross profit as a percentage of sales decreased to 61.1% for the third quarter of 2009 from 62.2% for the same period in the prior year. The decrease in gross profit percentage was primarily due to product mix.

Research and development expenses. Research and development (“R&D”) expenses increased by $737,000, or 19%, to $4.7 million in the third fiscal quarter of 2009. The increase is primarily due to increased engineering personnel to support IRE development and commercialization activities as $2.1 million was spent on the program in the third quarter of fiscal 2009. As a percentage of net sales, R&D expenses were 9.5% for the fiscal third quarter of 2009, compared with 9.7% for the same prior year period. At February 28, 2009, we employed 75 people in research, development and regulatory activities compared with 55 people in the prior year quarter.

Sales and marketing expenses. Sales and marketing (“S&M”) expenses increased $1.9 million or 16% to $13.7 million in the third quarter of fiscal 2009. Sales expenses accounted for $1.2 million of the increase, which represented a 13% increase over the prior year, due to personnel expenses related to the increased number of sales territories under the program to expand our Peripheral Vascular and Access sales forces with the addition of 19 new sales representatives, personnel hired in the Diomed acquisition and IRE sales activities. Marketing expenses increased approximately $700,000, or 27%, over the prior year period, primarily due to IRE marketing activities, increased headcount, costs relating to the Diomed acquisition, and additional tradeshows activities. As a percentage of net sales, S&M expenses were 27.6% for the fiscal third quarter of 2009, compared with 28.8% for the prior year period. $340 thousand was spent on IRE sales and marketing activity in the third quarter of fiscal 2009. At February 28, 2009, we employed 185 people in sales and marketing activities, of whom 13 were added in conjunction with the Diomed acquisition, compared with 153 people in the prior year quarter.

General and administrative expenses. General and administrative (“G&A”) expenses increased $3.5 million, or 100%, to $6.9 million primarily due to $2.8 million in transition costs for the CEO position with the remaining due to increased headcount for infrastructure growth across the administrative functions and business unit general management costs, partially offset by reduced legal expenses from now resolved litigation. G&A expenses were 14.0% of net sales, or 8.3% of net sales excluding the CEO transition costs, for the 2009 fiscal third quarter as compared with 8.4% for the prior year third fiscal quarter. As of February 28, 2009, we employed 53 people in general and administrative activities, of whom 5 were added in conjunction with the Diomed acquisition, compared with 36 people in the prior year period.

Amortization of intangibles. Amortization of intangibles increased to $2.3 million in the third quarter of fiscal 2009, from $1.8 million in the same period of the prior year. The increase is primarily attributable to the amortization of intangibles acquired in the acquisitions of Oncobionic and Diomed. Amortization of IRE intangibles was $430 thousand in the third quarter of fiscal 2009.

Gain on litigation settlement. For the three months ended February 28, 2009, there was no litigation provision (gain on settlement) as compared to the same period of the prior year when the settlement of the Diomed litigation, which occurred on April 2, 2008, provided a gain of $3.2 million.

Operating income. Operating income was $2.6 million and $7.6 million for the third quarter of fiscal 2009 and 2008, respectively. As a percentage of sales, operating income for the third quarter of 2009 was 5.3% and would have been 11.0% excluding the aforementioned CEO transition costs, compared with 18.7% in the prior year same period. The prior year period included a $3.2 million gain related to favorable settlement of outstanding litigation. Without the settlement gain, the prior year period would also have been 10.9% of sales.

Other income (expenses). Other income and expenses for the third quarter of fiscal 2009 decreased $145,000 compared with the same period of the prior year due primarily to decreased interest income on reduced cash balances and lower investment returns as a result of market conditions offset by a gain on an interest rate swap compared with a loss a year ago and lower interest expense as a result of the payment of the Convertible Notes assumed in the acquisition of RITA.

Income taxes. Our effective tax rate for the 2009 third fiscal quarter was 29.8% compared to 37.6% a year ago. The current quarter benefited from increased research and development tax credits.

Net income. For the third quarter of 2009, we reported net income of $1.9 million, a decrease of $3.0 million, from net income of $4.9 million for the prior year third quarter primarily due to CEO transition costs included in the current period and the inclusion of the gain related to the favorable settlement of outstanding litigation in the prior year period.

### Nine Months ended February 28, 2009 and February 29, 2008

Financial Summary. For the first nine months of fiscal 2009, we reported net income of $7.0 million, or $0.29 per diluted common share, on net sales of $142.2 million, compared with net income of $10.4 million, or $0.43 per diluted common share, on net sales of $119.7 million in the first nine months of the prior year. Gross profit percentage improved to 61.4% for the first nine months of 2009 from 61.2% one year ago.

The following table sets forth certain operating data as a percentage of net sales:

|  | Nine Months Ended February 28, 2009 | February 29, 2008 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 61.4% | 61.2% |
| Research and development expenses | 9.2% | 8.7% |
| Sales and marketing expenses | 28.6% | 28.0% |
| General and administrative expenses | 10.8% | 9.7% |
| Amortization of intangibles | 4.8% | 4.2% |
| Gain on litigation settlement | 0.0% | -2.6% |
| Operating income | 8.0% | 13.3% |
| Other income(expenses) | -0.5% | 0.6% |
| Net income | 4.9% | 8.7% |

Net sales. Net sales for the fiscal first nine months of 2009 increased by 19%, or $22.5 million, to $142.2 million, from $119.7 million in the fiscal first nine months of 2008. $14.2 million of the $22.5 million increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. The balance of the growth in net sales was primarily attributable to increased unit sales of LC Bead, SmartPort CT, the Morpheus insertion kits and Angiographic products.

From a business unit perspective, Peripheral Vascular sales increased 33% to $60.9 million from $45.9 million. $14.2 million of the increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. Laser ablation sales increased from $9.5 million in the fiscal first nine months of 2008 to $23.7 million in the fiscal first nine months of 2009, reflecting the acquisition of Diomed and the integration of the VenaCure EVLT product line. Access sales were $48.9 million, an increase of 6%, primarily attributable to increased unit sales of SmartPort CT and the Morpheus insertion kits. Oncology/Surgery sales were $32.4 million, an increase of 18% over the prior year, primarily as a result of strong sales of our chemoembolization product, LC Bead.

From a geographical perspective, US sales increased $17.6 million or 16.3% in the first nine months of 2009 to $126.3 million from $108.6 million a year ago. Approximately $9.1 million of this increase is attributable to the sales of products acquired from Diomed. The balance of this increase is primarily attributable to increased unit sales of LC Bead, SmartPort CT, Morpheus insertion kits and Angiographic products. International sales increased $4.8 million or 43.5% in the first nine months of 2009 to $15.9 million from $11.1 million a year ago. This increase is attributable to the sales of products acquired from Diomed, offset by decreased sales of our RF Ablation devices.

Gross profit. Our gross profit as a percentage of sales increased to 61.4% for the first nine months of 2009 from 61.2% for the same period in the prior year. The increase in gross profit percentage was attributable to product mix.

Research and development expenses. Research and development (“R&D”) expenses increased by $2.7 million, or 26%, to $13.1 million in the first nine months of 2009. The increase is primarily due to increased engineering personnel to support IRE development and commercialization activities as $5.2 million was spent on the program in the first nine months of fiscal 2009. As a percentage of net sales, R&D expenses were 9.2% for the first nine months of fiscal 2009, compared with 8.7% for the same prior year period.

Sales and marketing expenses. Sales and marketing (“S&M”) expenses increased $7.2 million or 22% to $40.7 million in the first nine months of fiscal 2009. Sales expenses accounted for $4.8 million of the increase, which represented an 18% increase over the prior year, due to personnel expenses related to the increased number of sales territories under the program to expand our Peripheral Vascular and Access sales forces, personnel hired in the Diomed acquisition and IRE sales activities. Marketing expenses increased $2.4 million, or 34%, over the prior year period, primarily due to IRE marketing activities, increased headcount, costs related to the Diomed acquisition and additional marketing initiatives as a result of the new business unit strategy. As a percentage of net sales, S&M expenses were 28.6% for the first nine months of 2009, compared with 28.0% for the prior year period. $780 thousand was spent on IRE sales and marketing activity in the first nine months of fiscal 2009.

General and administrative expenses. General and administrative (“G&A”) expenses increased $3.8 million, or 32.7%, to $15.4 million for the first nine months of 2009 as compared to the prior year. This increase was primarily due to $3.0 million of costs associated with the CEO transition. The remaining increase is due to increased headcount for infrastructure growth across the administrative functions and business unit general management costs partially offset by reduced legal expenses from now resolved litigation. G&A expenses were 10.8% of net sales for the 2009 fiscal first nine months, or 8.7% excluding the CEO transition costs, compared with 9.7% for the prior year period.

Amortization of intangibles. Amortization of intangibles increased to $6.8 million in the first nine months of fiscal 2009, from $5.0 million in the same period of the prior year. The increase is primarily attributable to the amortization of intangibles acquired in the acquisitions of Oncobionic and Diomed. Amortization of IRE intangibles was $1.3 million in the first nine months of fiscal 2009.

Gain on litigation settlement. For the nine months ended February 28, 2009, there was no litigation provision (gain on settlement) compared with the same prior year period when the settlement of the Diomed litigation, which occurred on April 2, 2008, resulted in a gain of $3.2 million.

Operating income. Operating income was $11.3 million and $15.9 million for the first nine months of fiscal 2009 and 2008, respectively. As a percentage of sales, operating income for the first nine months of 2009 was 8.0% compared to 13.3% in the prior year same period. Excluding the CEO transition costs, operating income would have been 10.1% for the 2009 period. The prior year period included a $3.2 million gain related to favorable settlement of outstanding litigation. Without the gain, the prior year period would have been 10.7% of sales.

Other income (expenses). Other income and expenses for the first nine months of fiscal 2009 decreased $1.3 million compared with the same period of the prior year due primarily to $1.3 million less interest income on reduced cash balances and lower investment returns as a result of market conditions and $305,000 of foreign exchange losses. These amounts were offset by lower interest expense as a result of the payment of the Convertible Notes assumed in the acquisition of RITA.

Income taxes. Our effective tax rate was 34.2% for the first nine months of 2009 compared with 37.5% a year ago. The current year to date period benefited from R&D tax credit utilization. The R&D tax credit expired on December 31, 2007 and was reinstated on October 3, 2008. The reinstatement retroactively extended R&D tax credits from January 1, 2008 to December 31, 2009. The retroactive impact is reflected in our current year to date tax rate.

Net income. For the first nine months of 2009, we reported net income of $7.0 million, a decrease of $3.4 million, from net income of $10.4 million for the prior year period. This decrease is primarily related to CEO transition costs in the current period and the inclusion of the gain related to the favorable settlement of outstanding litigation in the prior year period.

### Liquidity and Capital Resources

Our cash, cash equivalents and marketable securities totaled $62.3 million at February 28, 2009, compared with $78.3 million at May 31, 2008. Marketable securities are comprised of U.S. government issued or guaranteed securities, corporate bonds and auction rate securities. At February 28, 2009, total debt was $7.2 million comprised of short and long-term bank debt that financed our facility expansions in Queensbury, New York. This compared with $17.1 million at May 31, 2008 which also included $9.7 million of convertible debt assumed in the RITA acquisition which was paid upon maturity in the first quarter of 2009.

Net cash provided by operating activities for the nine months ended February 28, 2009 was $13.0 million compared with $20.1 million in the same prior year period. Cash generated from operating activities during the first nine months of fiscal year 2009 was primarily the result of net income and the effect on net income of non cash items, such as depreciation and amortization, stock-based compensation and the provision for deferred income taxes, as well as a decrease in accounts receivable offset by increases in inventories and the $6.7 million litigation settlement paid to VNUS Medical.

Net cash used in investing activities was $10.0 million for the nine months ended February 28, 2009 compared with net cash used of $7.8 million for the same prior year period. The net cash used in fiscal 2009 consisted of $10.1 million for the acquisition of Diomed assets, $5.0 million for the contractual Oncobionic payment, $1.4 million for the acquisition of FlowMedica assets and fixed asset additions of $3.5 million, offset by net proceeds from the sale, maturity and purchase of available-for-sale short term investments.

Net cash used in financing activities was $8.2 million for the nine months ended February 28, 2009 compared with cash provided by financing activities of $3.0 million for the comparable prior year period. Cash used in financing activities for the nine months ended February 28, 2009 primarily consisted of payment of convertible note and long-term debt obligations of $10.0 million offset by proceeds from the exercise of stock options and ESPP of $1.8 million.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2008 with the exception of the convertible debt, including interest totaling $10.1 million and the $6.8 million litigation settlement which were both paid in the first quarter of fiscal 2009. In addition, we paid a $5.0 million installment in November 2008 in connection with the Oncobionic acquisition.

In fiscal 2003, we financed an expansion of our headquarters and manufacturing facility with industrial revenue bonds for $3.5 million. To secure this financing, we entered into agreements with local municipalities, a bank, a trustee and a remarketing agent. These agreements are referred to as the IDA agreements. The proceeds of the bonds were advanced as construction occurred. The bonds reprice every seven days and are resold by a Remarketing Agent. The bonds bear interest based on the market rate on the date the bonds are repriced and require quarterly principal payments ranging from $25,000 to $65,000 plus accrued interest through May 2022. We entered into an interest rate swap with a bank to convert the initial variable rate payments to a fixed interest rate of 4.45% per annum. The IDA agreements contain financial covenants relating to fixed charge coverage and interest coverage. The outstanding debt is collateralized by a letter of credit ($2.4 million at February 28, 2009) and a first mortgage on the land, building and equipment comprising our facility in Queensbury, and we are required to pay an annual fee ranging from 1.0% to 1.9% of the outstanding balance depending on our financial results. The current fee is 1.0% and is in effect until August 22, 2009.

In fiscal 2007, we financed the expansion of our warehouse and manufacturing facility in Queensbury, New York. The expansion was financed principally with taxable adjustable rate notes (the “Notes”) issued by us aggregating $5,000,000 and maturing in 2026. The Notes were issued under a trust agreement by and between us and a bank, as trustee (the “Trustee”). In connection with the issuance of the Notes, we entered into a letter of credit and reimbursement agreement (the “Reimbursement Agreement”) with the Bank that requires the maintenance of a letter of credit to support principal and certain interest payments on the Notes and requires payment of an annual fee on the outstanding balance. The current fee is 0.75% and is in effect until December 2009. We also entered into a remarketing agreement, pursuant to which the remarketing agent is required to use its best efforts to arrange for sales of the Notes in the secondary market. In connection with this financing, we entered into an interest rate swap agreement (the “2006 Swap Agreement”) with the Bank, effective December 2006, with an initial notional amount of $5,000,000, to limit the effect of variability due to interest rates on the rollover of the Notes. The 2006 Swap Agreement is a contract to exchange floating interest rate payments for fixed interest payments periodically over the life of the agreement without the exchange of the underlying notional amounts. The 2006 Swap Agreement requires us to pay a fixed rate of 5.06% and receive payments based on 30-day LIBOR repriced every seven days through December 2016. The Reimbursement Agreement contains certain financial covenants relating to fixed charge coverage and interest coverage, as defined. Amounts borrowed under the Reimbursement Agreement are collateralized by the aforementioned letter of credit and all of our assets. The debt covenants and the collateralization of substantially all of our assets to secure these financings may restrict our ability to obtain debt financing in the future.

During the nine months ended February 28, 2009, the Convertible Notes assumed in the acquisition of RITA on January 29, 2007 with an aggregate principal amount of $9.7 million matured and were paid in cash.

On May 9, 2008, we completed the acquisition of all the issued and outstanding shares of capital stock of Oncobionic, Inc. pursuant to the terms of a stock purchase agreement entered into on October 12, 2006. The closing of the acquisition came as a result of the successful use of Oncobionic’s irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008. Under this stock purchase agreement, we agreed to pay a total purchase price of $25.4 million, including $400,000 of assumed liabilities. We made a payment of $5.0 million upon the execution of the stock purchase agreement in October 2006. We paid $10.0 million on May 9, 2008 upon the closing of the acquisition and $5.0 million in November 2008. The remaining $5.0 million is payable in November 2009.

We believe that our current cash and investment balances, together with cash generated from operations, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant additional acquisitions of other businesses or technologies for cash, we will, in all likelihood, require additional financing. We cannot assure you that such financing will be available on commercially reasonable terms, if at all.

## Market risk

As filed, 2,258 characters.

We are exposed to market risk from changes in interest rates on investments and financing that could impact our results of operations and financial position. Although we have entered into interest rate swaps with a bank to limit our exposure to interest rate change on our variable interest rate financings, we do not currently engage in any other hedging or market risk management tools.

At February 28, 2009, we maintained variable interest rate financing of $7.1 million in connection with our facility expansions. We have limited our exposure to interest rate risk by entering into interest rate swap agreements with a bank under which we agreed to pay the bank fixed annual interest rate of 4.45% and 5.06% and the bank assumed our variable interest payment obligations under the financing.

Approximately 5% of our sales in the first nine months of fiscal 2009 were denominated in currencies other than the US dollar, primarily the Euro and GB pound.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investments. ARS typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have $1.85 million in investments in two auction rate securities issued by New York state agencies that have failed auctions. The State of New York is current in its interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business as described in Note L.

## Controls and procedures

As filed, 1,437 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiaries) in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting in the fiscal quarter ended February 28, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 705 characters.

Item 1A, (“Risk Factors”) of our annual report on Form 10-K for our fiscal year ended May 31, 2008 sets forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. There have been no material changes from the Risk Factors described in our annual report on Form 10-K; however, those Risk Factors continue to be relevant to an understanding of our business, financial condition and operating results and, accordingly, you should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk.

Filed Apr 9, 2009.
Source: SEC EDGAR, the filing index for accession 0001193125-09-076451. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
